Scopio on the future of telehematology
Through full-field digital cell morphology, Scopio Labs’ technology can automate the analysis of tens of…
Through full-field digital cell morphology, Scopio Labs’ technology can automate the analysis of tens of…
One of the biggest global challenges facing healthcare systems is bacteria and viruses becoming resistant…
pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic…
Labiotech recently interviewed Nathan Buchbinder, chief product officer at Proscia, about digital pathology. AI has…
Discovering new drugs remains an inefficient, trial and error-based process. The founding team behind the…
The news last week of the FDA approving Ferring Pharmaceuticals' first fecal microbiome product, Rebyota,…
Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in…
The majority of known rare genetic diseases affect children, and gene therapies could help them…
2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO…
The California-based Molecular Devices brings automated 3D cell culture and image analysis together with HeartBeat.bio’s…
The first generation of microbiome therapeutics is hitting its first approvals. Savita Bernal, chief business…
AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the…